Source MDx is developing and commercializing prognostic, predictive and early detection molecular diagnostic (Precision Profile ) assays and tests for cancer and other inflammatory diseases. The company's lead development programs, in collaboration with the Dana-Farber Cancer Institute, includes a family of Precision Profile assays for prostate cancer designed to: improve early diagnosis with a goal to reduce the need for biopsies, predict the aggressiveness of the cancer, better define prognosis and more effectively stratify patients for drug response - all of which may serve to improve the management of patient care and lower healthcare costs.
Missing: SourceMDx's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: SourceMDx's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing SourceMDx
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
SourceMDx is included in 1 Expert Collection, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
SourceMDx Frequently Asked Questions (FAQ)
When was SourceMDx founded?
SourceMDx was founded in 1998.
Where is SourceMDx's headquarters?
SourceMDx's headquarters is located at 2500 Central Avenue, Boulder.
What is SourceMDx's latest funding round?
SourceMDx's latest funding round is Dead.
How much did SourceMDx raise?
SourceMDx raised a total of $1.51M.
Who are the investors of SourceMDx?
Investors of SourceMDx include Pfizer Venture Investments.
Who are SourceMDx's competitors?
Competitors of SourceMDx include Oxford BioDynamics, AltheaDx, CivaTech Oncology, Ikonisys, Binx Health, Oxford Immunotec, Mauna Kea Technologies, Saladax Biomedical, Akonni Biosystems, Exagen and 20 more.
Compare SourceMDx to Competitors
CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
FMI Medical Systems is developing ultra high resolution PET/CT/SPECT diagnostic imaging systems combined with drugs and molecular tracers for earliest detection and monitoring of Alzheimer's, neurodegenerative disorders, and head and neck cancers and breast cancer.
MND Diagnostics is a healthcare company focused on disease diagnosis. The medical device company has developed a diagnostic detection platform which aims to be rapid, low-priced and portable.
NeoDiagnostix develops molecular diagnostic and prognostic tests for the treatment of cancer. The company's test results eliminate the ambiguity experienced in millions of samples analyzed by traditional cytomorphology-based cell analyses. The company is committed to providing physicians with information that will improve patient care and treatment.
Micrima is a Bristol-based company developing a safe, low-cost system to improve the detection of breast cancer. The imaging system captures high-resolution, 3D images through the use of harmless radio waves. The safe, low-cost system enables women of all ages to be screened for breast cancer in GP surgeries, or alternative high street locations, with results that are now comparable with traditional X-ray mammograms.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.